Systemically delivered antisense oligomers upregulate gene expression in mouse tissues

Systemically injected 2′-O-methoxyethyl (2′-O-MOE)-phosphorothioate and PNA-4K oligomers (peptide nucleic acid with four lysines linked at the C terminus) exhibited sequence-specific antisense activity in a number of mouse organs. Morpholino oligomers were less effective, whereas PNA oligomers with only one lysine (PNA-1K) were completely inactive. The latter result indicates that the four-lysine tail is essential for the antisense activity of PNA oligomers in vivo. These results were obtained in a transgenic mouse model designed as a positive readout test for activity, delivery, and distribution of antisense oligomers. In this model, the expressed gene (EGFP-654) encoding enhanced green fluorescence protein (EGFP) is interrupted by an aberrantly spliced mutated intron of the human β-globin gene. Aberrant splicing of this intron prevented expression of EGFP-654 in all tissues, whereas in tissues and organs that took up a splice site-targeted antisense oligomer, correct splicing was restored and EGFP-654 expression upregulated. The sequence-specific ability of PNA-4K and the 2′-O-MOE oligomers to upregulate EGFP-654 provides strong evidence that systemically delivered, chemically modified oligonucleotides affect gene expression by sequence-specific true antisense activity, validating their application as potential therapeutics.

[1]  R Kole,et al.  Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[2]  E. Richelson,et al.  Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. , 2002, Antisense & nucleic acid drug development.

[3]  P. Iversen,et al.  In vivo evaluation of a morpholino antisense oligomer directed against tumor necrosis factor-alpha. , 2000, Antisense & nucleic acid drug development.

[4]  R Kole,et al.  Modification of alternative splicing pathways as a potential approach to chemotherapy. , 2000, Pharmacology & therapeutics.

[5]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[6]  S. Agrawal,et al.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Levin,et al.  Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[8]  Rosie Yu,et al.  Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis , 2000, Nature Biotechnology.

[9]  I Lebedeva,et al.  Antisense oligonucleotides: promise and reality. , 2001, Annual review of pharmacology and toxicology.

[10]  M. Manoharan,et al.  Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. , 2001, Nucleic acids research.

[11]  S. Agrawal,et al.  Pharmacokinetics of Antisense Oligonucleotides , 1995, Clinical pharmacokinetics.

[12]  R. Kole,et al.  Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. , 2001, Current cancer drug targets.

[13]  R. Kole,et al.  Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense Oligonucleotides , 1999, Pharmaceutical Research.

[14]  B. Graveley.  Alternative splicing: increasing diversity in the proteomic world. , 2001, Trends in genetics : TIG.

[15]  K. Stecker,et al.  Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides. , 2000, The Journal of investigative dermatology.

[16]  T. Misteli,et al.  Correction of Alternative Splicing of Tau in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17* , 2001, The Journal of Biological Chemistry.

[17]  S. Agrawal,et al.  Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides , 1999, Neuromuscular Disorders.

[18]  M. Manoharan,et al.  Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. , 1998, Human molecular genetics.

[19]  E. Lesnik,et al.  Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[20]  J. Karras,et al.  Deletion of individual exons and induction of soluble murine interleukin-5 receptor-alpha chain expression through antisense oligonucleotide-mediated redirection of pre-mRNA splicing. , 2000, Molecular pharmacology.

[21]  David R Corey,et al.  Morpholino antisense oligonucleotides: tools for investigating vertebrate development , 2001, Genome Biology.

[22]  R. Kole,et al.  Antisense effects in the cell nucleus: modification of splicing. , 2001, Current opinion in molecular therapeutics.

[23]  M. Knowles,et al.  Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.

[24]  N. Dean,et al.  Preclinical and clinical pharmacology of antisense oligonucleotides , 1999, Molecular biotechnology.

[25]  P. Iversen,et al.  Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. , 2002, Journal of pharmaceutical sciences.

[26]  International Human Genome Sequencing Consortium.  Initial sequencing and analysis of the human genome , 2001, Nature.

[27]  C. Bortner,et al.  Modification of Alternative Splicing of Bcl-x Pre-mRNA in Prostate and Breast Cancer Cells , 2001, The Journal of Biological Chemistry.

[28]  M. Caruthers,et al.  Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. , 1997, Antisense & nucleic acid drug development.

[29]  Tomoko Nakanishi,et al.  ‘Green mice’ as a source of ubiquitous green cells , 1997, FEBS letters.

[30]  J. Wyatt,et al.  Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides , 1999, Nature Biotechnology.

[31]  R. Kole,et al.  Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. , 2002, Molecular pharmacology.

[32]  Gunther Hartmann,et al.  Antisense therapy in oncology: new hope for an old idea? , 2001, The Lancet.

[33]  S. Agrawal,et al.  Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Iversen,et al.  Transdermal delivery of antisense compounds. , 2000, Advanced drug delivery reviews.